🔎 Trials Near Me

Hjem › KOL › Oklahoma

KOL kliniske forsøg i Oklahoma

8 studier for KOL søger deltagere på steder i Oklahoma.

Byer i Oklahoma

Officiel studietekst (engelsk)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  • Research Site, Norman
  • Research Site, Oklahoma City
  • Research Site, Tulsa
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06283966

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

  • Layrek Clinical Research- Site Number : 8400066, Tulsa
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 1. okt. 2026 · NCT07190222

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  • Epic Medical Research - Chickasha- Site Number : 8400097, Chickasha
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 22. sep. 2026 · NCT07190209

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  • Research Site, Oklahoma City
  • Research Site, Tulsa
RekruttererFase 2
Alder 40 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07082738

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  • Research Site, Oklahoma City
  • Research Site, Tulsa
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  • Research Site, Oklahoma City
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06883305

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  • GSK Investigational Site, Edmond
RekruttererFase 3
Alder 40 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07177339

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

  • Hightower Clinical, Oklahoma City
RekruttererObservationsstudie
Alder 50 og opefter · Alle køn · Opdateret 5. aug. 2025 · NCT06122077

Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.